Share Name Share Symbol Market Type Share ISIN Share Description
Concepta LSE:CPT London Ordinary Share GB00BYZ2R301 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 5.70p 5.60p 5.80p 5.70p 5.70p 5.70p 0 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.1 -2.4 -2.0 - 7.88

Concepta PLC Result of AGM

14/06/2018 10:22am

UK Regulatory (RNS & others)


Concepta (LSE:CPT)
Historical Stock Chart

1 Month : From May 2018 to Jun 2018

Click Here for more Concepta Charts.

TIDMCPT

RNS Number : 4033R

Concepta PLC

14 June 2018

14 June 2018

Concepta plc

("Concepta" or the "Company")

Result of AGM

Concepta plc (AIM:CPT), the UK healthcare company and developer of a proprietary product targeted at the mobile health market and with a primary focus on women's fertility, is pleased to announce that at its Annual General Meeting ("AGM") held earlier today, Thursday 14 June 2018, all resolutions were duly passed.

-ENDS-

Enquiries:

The Company

Erik Henau

CEO

Tel: +44 (0) 1234 866601

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

NOVUM Securities Limited (Broker)

Colin Rowbury

Tel: +44 (0) 20 7399 9400

Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254

Notes to Editors

Concepta Plc

Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility in women.

myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH and human chorionic gonadotropin (hCG) hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.

Concepta has made significant progress recently, establishing relationships with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future.

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H2 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.GBP600m per annum.

Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGKZLBFVQFLBBB

(END) Dow Jones Newswires

June 14, 2018 05:22 ET (09:22 GMT)

1 Year Concepta Chart

1 Year Concepta Chart

1 Month Concepta Chart

1 Month Concepta Chart
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V:gb D:20180620 07:50:44